European Organisation for Research and Treatment of Cancer, United States Cutaneous Lymphoma Consortium and International Society for Cutaneous Lymphomas consensus recommendations for management and treatment of cutaneous lymphoproliferative disorders
British Journal of Dermatology · 2025
DOI: 10.1093/bjd/ljaf312 ↗Kurz gefasst
Leitlinie in der Zeitschrift British Journal of Dermatology, 2025. Verfasst von Rein Willemze und 38 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Leiden University Medical Center, Leiden, the Netherlands. Hauptthemen laut MEDLINE: Lymphoma, T-Cell, Cutaneous, Lymphoproliferative Disorders, Skin Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 70 Literaturangaben.
Abstract (Originalsprache)
In recent classifications several cutaneous lymphomas were reclassified as lymphoproliferative disorder (LPDs). These include primary cutaneous CD4+ small/medium T-cell LPD (PCSM-TCLPD), primary cutaneous acral CD8+ T-cell LPD (acral CD8+ TCLPD) and primary cutaneous marginal zone lymphoma/LPD (PCMZL/LPD). The latter is still classified as primary cutaneous marginal zone lymphoma (PCMZL) in the 5th edition of the World Health Organization classification. A survey was previously carried out among 30 cutaneous lymphoma centres on the effects of this new terminology on clinical management. The results revealed considerable heterogeneity and emphasized the need to develop uniform recommendations for management and treatment of these disorders. Our objective was to develop consensus recommendations for staging, treatment and follow-up in PCSM-TCLPD, acral CD8+ TCLPD and PCMZL/LPD. Two surveys with questions regarding staging, treatment and follow-up of cutaneous LPDs were distributed among 30 cutaneous lymphoma expert centres collaborating within the EORTC-CLTG, USCLC and ISCL. Consensus recommendations were formulated based on these surveys, an extensive literature search, two rounds of feedback and a final consensus meeting. Important changes compared with current practice and literature are as follows. (i) Staging examinations, other than thorough clinical examination of skin and peripheral lymph nodes, are not required in typical cases of PCSM-TCLPD and acral CD8+ TCLPD. (ii) Low-dose radiotherapy (4–8 Gy) can be used rather than dose ≥ 20 Gy for PCSM-TCLPD and acral CD8+ TCLPD, and 4 Gy can be used for PCMZL/LPD. The dose can be escalated to 20–24 Gy in the case of local failure. (iii) Intralesional corticosteroids are also recommended as initial treatment in all three LPDs. (iv) A limited follow-up period (2 years) is acceptable in PCSM-TCLPD and acral CD8+ TCLPD LPD. These EORTC/USCLC/ISCL consensus recommendations reflect the state-of-the-art management and treatment as agreed upon by major cutaneous lymphoma centres. They may contribute to uniform staging, treatment and follow-up policy in patients with cutaneous LPDs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Dermatology, Leiden University Medical Center, Leiden, the Netherlands.
ORCID-Profile: Rein Willemze, Marie Beylot-Barry, Christiane Querfeld, Maarten Vermeer, Marion Wobser
Zitieren
APA
Willemze, R., Assaf, C., Bagot, M., Beylot-Barry, M., Berti, E., Busschots, A. M., Cerroni, L., Climent, F., Diercks, G., Geskin, L., Gniadecki, R., Gru, A. A., Guenova, E., Guitart, J., Jansen, P., Kempf, W., Kim, E., Kim, Y. H., Koldijk, M., …, & Wobser, M. (2025). European Organisation for Research and Treatment of Cancer, United States Cutaneous Lymphoma Consortium and International Society for Cutaneous Lymphomas consensus recommendations for management and treatment of cutaneous lymphoproliferative disorders. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljaf312
Vancouver
Willemze R, Assaf C, Bagot M, Beylot-Barry M, Berti E, Busschots AM, et al. European Organisation for Research and Treatment of Cancer, United States Cutaneous Lymphoma Consortium and International Society for Cutaneous Lymphomas consensus recommendations for management and treatment of cutaneous lymphoproliferative disorders. British Journal of Dermatology. 2025. doi:10.1093/bjd/ljaf312
BibTeX
@article{Willemze2025,
author = {Willemze, Rein and Assaf, Chalid and Bagot, Martine and Beylot-Barry, Marie and Berti, Emilio and Busschots, Anne Marie and Cerroni, Lorenzo and Climent, Fina and Diercks, Gilles and Geskin, Larisa and Gniadecki, Robert and Gru, Alejandro A and Guenova, Emmanuella and Guitart, Joan and Jansen, Patty and Kempf, Werner and Kim, Ellen and Kim, Youn H and Koldijk, Marjolein and Marschalkó, Martá and Mitteldorf, Christina and Molgó, Montserrat and Muniesa, Cristina and Neelis, Karen J and Olsen, Elise and Ortiz-Romero, Pablo L and Papadavid, Evangelia and Pimpinelli, Nicola and Pulitzer, Melissa and Quaglino, Pietro and Querfeld, Christiane and Quint, Koen and Scarisbrick, Julia J and Schrader, Anne M R and Stadler, Rudolf and Vermeer, Maarten and Wehkamp, Ulrike and Whittaker, Sean and Wobser, Marion},
title = {European Organisation for Research and Treatment of Cancer, United States Cutaneous Lymphoma Consortium and International Society for Cutaneous Lymphomas consensus recommendations for management and treatment of cutaneous lymphoproliferative disorders},
journal = {British Journal of Dermatology},
year = {2025},
doi = {10.1093/bjd/ljaf312}
}
EUVIMED